<DOC>
	<DOCNO>NCT00051285</DOCNO>
	<brief_summary>To determine low-dose enoximone therapy effective treatment advance chronic heart failure .</brief_summary>
	<brief_title>ESSENTIAL- '' The Studies Oral Enoximone Therapy Advanced Heart Failure ''</brief_title>
	<detailed_description>The study randomize , double-blind , multicenter , parallel group , placebo-controlled trial oral enoximone approximately 700 subject advance chronic heart failure either ischemic nonischemic etiology receive optimal conventional heart failure therapy . Eligible subject randomize 1:1 ratio receive either enoximone placebo Randomization Visit . The initial dose study drug 25 mg t.i.d . ( 3xday ) administer immediately randomization . Subjects tolerate initial dose continue 25 mg t.i.d . least two week . After two week , eligible subject titrate 50 mg t.i.d . duration study .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enoximone</mesh_term>
	<criteria>In order consider eligible subject , follow entry criterion must meet : At least 18 year age ischemic nonischemic cardiomyopathy NYHA Class III IV one hospitalization , two outpatient visit , treatment worsen heart failure within 12 month require administration I.V . heart failure therapy LVEDD &gt; 3.2 cm/m2 &gt; =6.0 cm LVEF le equal 30 % concomitant treatment optimal conventional heart failure therapy Exclusion Criteria Subjects meet one follow criterion deem ineligible participation study : Subjects follow concomitant medication : Calcium antagonists amlodipine felodipine Flecainide , encainide , propafenone , dofetilide disopyramide Subjects receive I.V . positive inotropic agent within seven day Screening Visit Randomization Visit Subjects receive human Btype natriuretic peptide , include nesiritide , within seven day Screening Visit Randomization Visit Subjects receive oral I.V . phosphodiesterase III inhibitor ( PDEI III ) , include levosimendan cilostazol , within seven day Screening Visit Randomization Visit Subjects active hepatic ( screen serum total bilirubin &gt; = 3.0 mg/dl ( &gt; =51.3 umol/l ) , renal ( screen serum creatinine &gt; = 2.0 mg/dl ( =178.8 umol/l ) ) , hematologic , gastrointestinal , immunologic , endocrine , metabolic , central nervous system disease Subjects serum potassium &lt; 4.0 mEq/L &gt; 5.5 mEq/L ( &lt; 4.0 mmol/l &gt; 5.5 mmol/l ) Randomization Visit Subjects magnesium level &lt; 1.0 mEq/L ( &lt; 0.5 mmol/l ) Randomization Visit ( Visit 0 ) Subjects serum digoxin &gt; 1.2 ng/ml ( &gt; 1.5 nmol/l ) serum digitoxin &gt; 20 ng/ml ( &gt; 26.2 nmol/l ) Randomization Visit exclude . A target serum digoxin level &lt; =1.0 ng/ml ( &lt; =1.3 nmol/l ) recommend</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>CHF</keyword>
	<keyword>heart</keyword>
	<keyword>failure</keyword>
	<keyword>congestive</keyword>
	<keyword>enoximone</keyword>
	<keyword>phosphodiesterase</keyword>
	<keyword>inhibitor</keyword>
</DOC>